99
Akeso
9926.HK·HKEXGuangzhou CNFounded 20123,500 employees
Mid CapbiotechPublicOncology
Platform: PD-1/CTLA-4
Market Cap
$8B
All Drugs
4
Clinical Trials
5
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (9926.HK)
Loading 9926.HK stock data...
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Riluratamab | 992-6929 | Phase 2 | 1 | GIP-R | CKD | ||
| 992-6426 | 992-6426 | Phase 2 | 1 | JAK1 | UCNarcolepsy | ||
| Nidaglumide | 992-691 | Preclinical | 2 | CD38 | MG | ||
| 992-9448 | 992-9448 | Preclinical | 1 | GPRC5D | MelanomaMM |
SEC Filings & Financial Documents
SEC filings are not available for HKEX-listed companies.
Akeso trades on HKEX (CN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (4)